Sector
PharmaceuticalsOpen
₹46.73Prev. Close
₹50.86Turnover(Lac.)
₹0.45Day's High
₹52.65Day's Low
₹46.7352 Week's High
₹58.452 Week's Low
₹31.99Book Value
₹0.07Face Value
₹1Mkt Cap (₹ Cr.)
236.8P/E
0EPS
0Divi. Yield
02 Sep 2023
12:00 AM
AGM
Announcement Date: 02 Sep, 2023
9 Sep 2023
12:00 AM
BookCloser
22 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 4.73 | 4.73 | 4.73 | 4.64 |
Preference Capital | 0 | 0 | 0 | 0.1 |
Reserves | 0.73 | 10.16 | 13.71 | 8.64 |
Net Worth | 5.46 | 14.89 | 18.44 | 13.38 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 132.71 | 106.28 | 1.46 | 0.19 |
yoy growth (%) | 24.86 | 7,179.88 | 660 | -89 |
Raw materials | -96.85 | -80.24 | -0.35 | -0.08 |
As % of sales | 72.97 | 75.5 | 24.24 | 42.54 |
Employee costs | -14.09 | -10.8 | -0.83 | -2.13 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | 5.53 | 1.22 | -1 | -4.04 |
Depreciation | -1.91 | -1.66 | -0.34 | -0.29 |
Tax paid | -0.43 | 0.15 | 0.07 | 0 |
Working capital | 5.9 | 31.91 | -0.32 | 1.93 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 24.86 | 7,179.88 | 660 | -89 |
Op profit growth | 88.23 | -553.78 | -70.97 | 76.22 |
EBIT growth | 137.67 | -609.74 | -78.87 | 110.41 |
Net profit growth | 269.61 | -248.57 | -77.06 | 138.02 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sameer Goel
Independent Director
Jagdeep Dhavvan
Independent Director
Richa Gupta
Director
Vipul Goel
Company Sec. & Compli. Officer
Lakshay Prakash
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kimia Biosciences Ltd
Summary
Kimia Bio-sciences Limited (Formerly known Laurel Organics Limited) was incorporated in September, 1993 led by the Promoters, A K Bansal, K S Varma, Atul Sharma, A P Godiyal, D K Gupta and R K Bansal. The Company has own manufacturing of Bulk Drugs-APIs at its plant located at Gurgaon, Haryana. The Company is engaged into the business of Pharamaceutical products.The company set up a bulk drug manufacturing unit at Gurgaon, Haryana, at a project cost of Rs 10.41 cr. It came out with a public issue in Feb.95 to part-finance the project. Commercial production commenced in May 95. During the 1998-99, the company has become a sick industrial units.The Honble BIFR vide order dated 27th December, 2005 had deregistered the Company as Sick Industrial Undertaking on the ground that 100% of the capacity was utilized for manufacture of the intermediate products for M/s Ranbaxy Laboratoty Limfted (RLL) and , thereby, turning-out to be an ancillary industrial Undertaking. .The Honble AAIFR disposed the appeal of M/s Ranbaxy Lab. Ltd vide its Order dated 30.08.2006, directing them to file an application before the Hoble BIFR only to redress grievances. Therefore, M/s Ranbaxy Lab. Ltd had filed an application-dated 31.10.06 before the Honble BIFR, requesting them to consider issuance of appropriate corrective orders. The Board has re-confirmed its earlier order. Therefore, despite negative net worth, the Company is out of BIFR purview.During the year 2017-18, the Scheme of Arrangement for Am
Read More
What is the Kimia Biosciences Ltd share price today?
The Kimia Biosciences Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹50.05 today.
What is the Market Cap of Kimia Biosciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kimia Biosciences Ltd is ₹236.80 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Kimia Biosciences Ltd?
The PE and PB ratios of Kimia Biosciences Ltd is 0 and 726.39 as of 22 Jul ‘24
What is the 52 Week High and Low of Kimia Biosciences Ltd?
The 52-week high/low is the highest and lowest price at which a Kimia Biosciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kimia Biosciences Ltd is ₹31.99 and ₹58.4 as of 22 Jul ‘24
What is the CAGR of Kimia Biosciences Ltd?
Kimia Biosciences Ltd's CAGR for 5 Years at 15.26%, 3 Years at 0.11%, 1 Year at 38.02%, 6 Month at 37.39%, 3 Month at -5.64% and 1 Month at -5.81%.
What is the shareholding pattern of Kimia Biosciences Ltd?
The shareholding pattern of Kimia Biosciences Ltd is as follows:
Promoters - 74.94 %
Institutions - 0.38 %
Public - 24.68 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
